REGN7999

Phase 2Small molecule

Regeneron

REGN7999 is one of 58 small molecule programs targeting Beta-Thalassemia. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Beta-ThalassemiaActive, not recruiting

ThalassemiaActive, not recruiting

Beta-ThalassemiaPhase 2

Active, not recruiting

ThalassemiaPhase 2

Active, not recruiting

Competition

Competitive Landscape

84 competitors in Thalassemia

#DrugCompanyPhaseTrials

Legalon

BBukwang Pharmaceutical

Phase 3

1 2

Winrevair

Merck & Co.

Phase 2

1 3

Neoral

Novartis

Phase 2

1 4

Epogen

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Phase 2

1 5

Jakafi

Incyte

Phase 2

1 6

Droxia

TTheravia

Phase 2

2 7

Dacogen

Sun Pharma

Phase 2

2 8

Endari

EEmmaus Medical, Inc.

Phase 2

2 9

CTX001

Vertex Pharmaceuticals

Phase 3

1 10

Campath

GGenzyme, a Sanofi Company

Phase 2

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Active, not recruiting

Beta-Thalassemia

NCT06421636

Clinical

Trials by Indication[1]

Trial1 trial

A Trial to Learn if REGN7999 is Safe and Well Tolerated, and How it Works in the Body of Healthy Participants

Completed· Regeneron logo

Regeneron·Phase 1·NCT05481333·64 enrolled

Beta-Thalassemia1 trial

A PHASE 2, TWO-PART, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF SUBCUTANEOUSLY ADMINISTERED REGN7999 (AN INHIBITOR OF TMPRSS6) IN PARTICIPANTS WITH IRON OVERLOAD DUE TO NON-TRANSFUSION DEPENDENT β-THALASSEMIA

Active, not recruiting· Regeneron logo

Regeneron·Phase 2·NCT06421636·19 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for REGN7999. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — REGN7999 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for REGN7999. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Regeneron company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Regeneron

REGN7999

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Trial1 trial

Beta-Thalassemia1 trial

References

Drug Info

Quick Facts

Related News